Dr Andrew Futreal

Dr Andrew Futreal aims to accelerate the translation of genomic technologies into therapeutic applications. Before joining MD Anderson in July 2012, he was the co-director of the Cancer Genome Project at the Wellcome Trust Sanger Institute, where he continues to be an honorary faculty member. His chief scientific accomplishments include the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes, leading a pioneering effort in large-scale systematic cancer genomics leading to the identification the BRAF mutations in melanoma, ERBB2 mutations in non-small cell lung cancer and multiple new cancer genes in renal cell carcinoma. 

He received the NIH Public Service Award in 1995 for discovering the BRCA1 gene involved in subsets of breast and ovarian cancer. Dr. Futreal applies his knowledge of cancer genomics to improve both short-term and long-term patient outcomes extending to cancer survivorship.